Is the sublocade drug safe and who should be cautious?

What is the sublocade drug and how is it given

The sublocade drug is an extended-release injectable formulation of buprenorphine used as part of opioid agonist therapy. It is supplied for subcutaneous abdominal injection and must be administered by a trained healthcare professional in a clinical setting rather than taken home. Health Canada product information and the Notice of Compliance describe its approved Canadian forms and regulatory status. The FDA label also emphasises that SUBLOCADE is given by a healthcare provider and details administration and handling expectations for certified clinics.

For a concise summary of clinical uses and logistics, see our page on what sublocade is used for.

Top red flags to discuss with your prescriber before starting Sublocade

Below are the most important clinical and practical red flags that should trigger a detailed conversation with your prescriber. Each item explains why it matters and gives the single question to ask your provider.

1. You are not stable on transmucosal buprenorphine

Why it matters: Clinical protocols generally require stabilisation on transmucosal buprenorphine, such as Suboxone, before moving to the monthly depot injection to confirm tolerability and reduce the risk of precipitated withdrawal. What to ask: “Have I been medically stabilised on transmucosal buprenorphine and for how long before I can receive Sublocade?”

2. Concurrent heavy alcohol or benzodiazepine use

Why it matters: Combining central nervous system depressants with buprenorphine increases the risk of respiratory depression and sedation. Product labelling and clinical guidance call for careful assessment and monitoring when sedatives or alcohol are present. What to ask: “Do you recommend extra monitoring or a different treatment because I use benzodiazepines or drink heavily?”

3. Active, untreated respiratory disease

Why it matters: Buprenorphine can depress respiration in susceptible people. If you have severe asthma, COPD, or other breathing problems, the prescriber must weigh the risks and plan monitoring. What to ask: “Given my lung or breathing condition, is Sublocade safe for me and how will you monitor breathing after an injection?”

4. Significant liver impairment

Why it matters: Buprenorphine is metabolised in the liver and severe hepatic impairment changes drug exposure; product information requires clinicians to evaluate liver function before and during therapy. What to ask: “Have you reviewed my liver tests and do we need more testing before starting Sublocade?”

5. Pregnancy or breastfeeding potential

Why it matters: The safety of extended-release buprenorphine in pregnancy and breastfeeding requires specialist discussion. Many medications for opioid use disorder have pregnancy implications that need obstetric and addiction medicine collaboration. What to ask: “If I am pregnant, trying to conceive, or breastfeeding, what are the risks and alternatives for opioid treatment?”

6. Allergy to buprenorphine or formulation components

Why it matters: A history of allergic reaction to buprenorphine or any injection excipient makes Sublocade unsafe. What to ask: “Do I have any known allergies that make Sublocade unsafe for me?”

7. Injection-site infection risk or compromised skin

Why it matters: Sublocade is given subcutaneously in the abdomen; active skin infection, recent abdominal surgery, or implants near the injection site can increase complication risk. What to ask: “Is my abdomen free of infection or other issues that would prevent safe injection?”

8. Recent major surgery or device implantation

Why it matters: Recent abdominal procedures or implanted medical devices near the injection area may require alternative plans or timing adjustments. What to ask: “Have I recently had surgery or an implant that means I should delay injections?”

9. Current severe psychiatric instability or suicidality

Why it matters: Active psychiatric crises require integrated care planning, because initiation of any opioid agonist therapy should be combined with mental health support where needed. What to ask: “How will you coordinate psychiatric care and safety planning if I have active mental health symptoms?”

Who qualifies for Sublocade in Ontario and what clinicians check first

Eligibility typically includes a documented opioid use disorder and clinical stabilisation on transmucosal buprenorphine prior to transition to the depot injection, plus a medical assessment that covers respiratory status, liver function, pregnancy screening, allergies, and concurrent medications. Health Canada and the FDA labelling set these safety checkpoints and clinics follow them during intake. Clinics also collect identification, medication history, and relevant test results during assessment.

At Road To Recovery, new patients for opioid agonist therapy are triaged by a nurse and seen by a physician the same day they start, which can reduce delays in assessment and help determine eligibility for treatments like Sublocade. Confirm availability and location specifics with the clinic when you book an intake.

Common side effects and injection-site reactions that require urgent care

Expected, non-urgent side effects can include constipation, headache, nausea, and injection-site discomfort or swelling; these are described in Canadian pharmacy resources and the product monograph. More serious but rare reactions include severe allergic reactions, significant respiratory depression, or signs of deep infection at the injection site. The product labelling details adverse events and when monitoring is recommended.

When to seek immediate emergency care: difficulty breathing, chest pain, severe swelling or rapidly spreading redness at the injection site, high fever, fainting, or symptoms of a severe allergic reaction. For other concerning side effects, call your clinic promptly to get advice on whether you should be assessed in person.

Questions to ask your clinic or prescriber before agreeing to an injection

Bring this printable checklist to your appointment. Each question is direct and useful for intake staff and prescribers.

• Am I medically stabilised on transmucosal buprenorphine and how long should stability be demonstrated?
• Who will administer the injection and where will it be given?
• What immediate monitoring will occur after the injection and when can I expect follow-up?
• Do you need liver tests, pregnancy tests, or other labs before the first injection?
• How will you manage concurrent sedative, benzodiazepine, or alcohol use?
• What are the alternatives if I am not eligible for Sublocade?
• What injection-site signs should prompt emergency care versus a clinic call?
• How are psychiatric concerns or suicidal thoughts handled and who provides referrals?
• What paperwork or ID should I bring to my same-day intake appointment?
• Who is the emergency contact at the clinic for after-hours problems?

For a clinical overview of uses and local logistics, see our page on what sublocade is used for.

How Sublocade is administered in Ontario and what to expect at Road To Recovery

Sublocade injections are given in a clinical setting by a trained provider. Certified healthcare settings must verify administration by a provider and Canadian regulatory listings confirm the product is supplied for professional administration. At Road To Recovery, the same-day intake model—nurse triage followed by physician assessment—helps streamline the evaluation needed to determine if Sublocade is appropriate; psychiatry referrals can be arranged locally or virtually through partners such as CAMH and OTN to support integrated care. Confirm with the specific clinic location about appointment availability and whether Sublocade is offered there before you travel.

Common objections and misconceptions—answered clearly

Myth: Sublocade will make you permanently dependent. Answer: Sublocade contains buprenorphine, a medication for opioid use disorder that reduces craving and withdrawal; physical dependence on a prescribed medication differs from uncontrolled opioid addiction and is managed clinically with clear plans for tapering or transition. Discuss long-term goals with your prescriber.

Myth: You cannot stop once you start. Answer: Treatment plans are individual and reversible; any decision to stop should be medically supervised and discussed with your care team.

Myth: Injections are inherently more dangerous than daily medication. Answer: Injections remove daily dosing complexity and reduce diversion risk, but they require clinic visits and monitoring for injection-site reactions; safety depends on careful patient selection and follow-up as described in product information.

Final decision checklist and next practical steps

1. Review the red flags above and mark any that apply to you.
2. Bring the checklist questions to your intake appointment.
3. Confirm stabilisation on transmucosal buprenorphine if applicable.
4. Ensure recent liver tests and pregnancy screening if relevant.
5. Ask who will administer the injection and what the monitoring plan is.
6. Clarify emergency contacts and after-hours support.
7. Arrange psychiatry or mental health follow-up if you have active symptoms.
8. Discuss alternatives (Suboxone, methadone, Kadian) if Sublocade is unsuitable.
9. Confirm cost, coverage, or pharmacy provisioning at your clinic.
10. If you are ready, request a same-day intake or book an assessment through the clinic portal.

Frequently asked questions

Is the sublocade drug addictive and how is dependency managed?

Sublocade contains buprenorphine, an opioid partial agonist used to treat opioid use disorder. While physical dependence can occur with opioid medications, treatment with buprenorphine is a medically supervised therapy intended to reduce harm, cravings, and overdose risk. Management of dependence and long-term plans are part of clinical care and should be discussed with your prescriber.

Can I switch from Suboxone or methadone to the sublocade drug and how long does that take?

Switching from transmucosal buprenorphine formulations, such as Suboxone, to Sublocade is commonly done after a period of stabilisation on the transmucosal product; transitions from methadone require specialist planning and are more complex. Product labelling and clinical guidance outline criteria and timing for transitions, so ask your clinician about individual timelines and safety checks.

What injection-site problems should make me seek emergency care?

Seek emergency care for difficulty breathing, rapid or severe swelling, spreading redness with fever, high pain with wound discharge, fainting, or signs of a severe allergic reaction. For less severe redness, soreness, or small lumps, contact your clinic for triage.

Who cannot receive the sublocade drug because of medical reasons?

People with known allergy to buprenorphine or formulation components, those with severe untreated respiratory depression, unstable liver failure without specialist oversight, or active injection-site infection are examples of medical reasons that may preclude Sublocade until the issue is resolved. Clinicians use the product monograph and clinical judgment when assessing eligibility.

How do I arrange an assessment or same-day intake for Sublocade at Road To Recovery?

Road To Recovery offers same-day intake for new opioid agonist therapy patients, with nurse triage followed by physician assessment the same day to reduce delays in starting treatment. Contact your local Road To Recovery clinic or use the secure online intake portal to request an assessment and confirm whether Sublocade is offered at that location before your appointment.

Ready to be assessed? Start a secure intake at Road To Recovery: the official website

Talk with Road To Recovery

Contact Road To Recovery to ask about the next step and confirm which options fit your needs.